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ABSTRACT
Hypertrophic cardiomyopathy used to be regarded as a rare untreatable cause of sudden death in young male athletes. 
This report is the case of a middle-aged female patient with hereditary hypertrophic cardiomyopathy masked by 
superimposed pericarditis and revealed by autopsy. This case report illustrates how co-morbidity can hide a crucial 
diagnosis. This case report also illustrates the value of autopsy disclosing a familial disease that is increasingly recognized 
and dramatically more treatable than a few decades ago. Sudden death due to hypertrophic cardiomyopathy has become 
preventable, if the diagnosis is made soon enough. The lessons for patient care from this case include the importance 
of not missing the diagnosis of hypertrophic cardiomyopathy in female patients. 
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CASE REPORT
This 42-year-old black female in the Midwest USA 
had a history of heart failure, hypertension, intravenous 
heroin and cocaine use, hepatitis B, hepatitis C, 
ethanol abuse, smoking, schizophrenia, depression, 
and three episodes of subacute endocarditis 3-4 years 
prior. She had been resident in a drug and alcohol 
rehabilitation center for ten months. Her chronic 
medications included nadolol, spironolactone, and 
sertraline.
The patient was admitted to the hospital with 
dyspnea and sharp left-sided chest pain of gradual 
onset for 48 hours, worse with movement, inspiration 
and the supine position. She had a parasternal 
high-pitched pansystolic heart murmur, increased with 
inspiration. Her abdomen was protuberant with a fluid 
wave. Her troponin was <0.08 ng/mL and erythrocyte 
sedimentation rate 28 mm/hr (reference range [RR]: 
<20 mm/hr). The next day, computed tomography 
scan showed a large pericardial effusion with evidence 
of cardiac tamponade, marked cardiomegaly and 
a markedly dilated right ventricle. Echocardiogram 
showed a pericardial effusion estimated to be 300 mL. 
The patient was discharged that day on indomethacin, 
furosemide, spironolactone, carvedilol, irbesartan, 
olanzapine and sertraline. Blood cultures were 
negative.
Three days later, on a Friday afternoon, the patient 
was brought to the emergency department with sharp, 
left-sided chest pain, rated 7/10, worse with breathing 
and movement, associated with gradually worsening 
dyspnea. She also had right lower back pain, rated 
7/10, for one day. Her temperature was 35 degrees C, 
pulse 84/minute, blood pressure 103/74 mm Hg and 
respirations 22/minute. She had pulmonary crackles 
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one-third of the way up her back, S3 and S4 gallops, 
a grade 2/6 systolic murmur at the left sternal border 
and right costovertebral angle tenderness. Chest x-ray 
showed marked cardiomegaly and pulmonary edema. 
Her troponin was 0.13 ng/mL (RR: <0.08 ng/mL), 
B-type natriuretic peptide 229 pg/mL (RR: <80 pg/mL), 
creatinine 2.3 mg/dL (RR: 0.5-1.4 mg/dL), glucose 
152 mg/dL (RR: 70-110 mg/dL) ,  hemoglobin 
13.8 g/dL (RR: 11.7-15.7 g/dL), white blood cell count 
9,100/mm3 (RR: 3,800-10,600/mm3), and platelet 
count 206,000/mm3 (RR: 156,000-369,000/mm3). 
Electrocardiogram showed sinus rhythm and nonspecific 
ST-segment and T-wave changes. She was admitted to 
the hospital and treated with intravenous furosemide 
(one 40 mg dose) and intravenous ketorolac, along with 
continuing indomethacin, furosemide, spironolactone, 
carvedilol, irbesartan, olanzapine and sertraline. 
She had diuresis of 700 mL, with improvement in 
her symptoms, pulse 74/minute, blood pressure 
123/88 mm Hg and respirations 24/minute.
On Saturday, the patient had increased dyspnea, 
chest pain and back pain. Urgent echocardiogram 
showed a large pericardial effusion with diastolic 
collapse of the right atrium, right ventricular 
dysfunction with dilatation and hypokinesis, evidence 
of moderate-severe pulmonary hypertension, 
moderate-severe tricuspid regurgitation, thickening 
of the mitral valve chordae tendineae, mild mitral 
regurgitation and left ventricular hypertrophy with 
preserved systolic function and an ejection fraction of 
65%; wall thicknesses were not measured. The patient 
was rushed to the operating room where she was 
found to have diffuse fibrinous pericarditis; 965 mL 
of bloody fluid were drained, a pericardial window 
created and a pericardial drain placed. Intraoperatively, 
the patient’s platelet count was 292,000/mm3, 
international normalized ratio (INR) 1.3 (RR: 0.8-1.2) 
and partial thromboplastin time (PTT) 32 seconds 
(RR: 25-33 seconds). Gram stain of the pericardial fluid 
showed very rare polymorphonuclear leukocytes and 
no organisms; aerobic, anaerobic, mycobacterial and 
fungal cultures all subsequently returned negative. 
Cytology of the pericardial fluid showed red blood cells, 
lymphocytes, macrophages and occasional mesothelial 
cells. Pericardial biopsy demonstrated acute fibrinous 
and organizing pericarditis. Following surgery, the 
patient had markedly improved oxygenation, but 
electrocardiogram revealed atrial fibrillation and a new 
incomplete right bundle branch block.
On Sunday, at 04:00, the patient’s heart rate 
was 143/minute, blood pressure 110/79 mm Hg and 
respirations 34/minute. 200 mL of pericardial fluid had 
been drained following surgery. At 16:00, her heart 
rate was 142/minute and blood pressure 94/69 mm Hg. 
At 16:58, electrocardiogram showed supraventricular 
tachycardia. The patient was given furosemide and 
diltiazem. Her respiratory function deteriorated and 
she was put on mechanical ventilation. At 18:14, 
chest x-ray showed bilateral airspace disease and 
pleural effusions. At 20:00, the patient’s heart 
rate was 98/minute, but blood pressure 95/67 mm 
Hg. Diltiazem was discontinued and infusions of 
amiodarone and phenylephrine started. At 21:36, she 
was given atropine. At 23:40, arterial blood showed 
PCO2 48 mm Hg and PO2 52 mm Hg (on 100% oxygen 
and 5 cm H2O of positive end-expiratory pressure).
At midnight, the patient’s heart rate was 74/minute, 
blood pressure 93/56 mm Hg and respirations 
44/minute. At 01:30, an infusion of dobutamine was 
started. At 01:55, the patient’s central venous pressure 
was 38 mm Hg and an infusion of epinephrine was 
added. At 02:00, the patient became bradycardic 
(with a heart rate of 30-40/minute) and profoundly 
hypotensive (systolic blood pressure 70 mm Hg). 
Amiodarone was stopped and her heart rate increased 
to 60-70/minute. At 02:16, arterial blood showed 
PCO2 50 mm Hg and PO2 56 mm Hg (on 100% oxygen 
and 10 cm H2O of positive end-expiratory pressure). 
The patient’s central venous pressure was >40 mm Hg 
and her heart rate dropped to 20-30/minute, with no 
pulse despite paced beats, epinephrine, bicarbonate 
and ongoing infusions of epinephrine, phenylephrine 
and dobutamine. She was pronounced dead at 02:56.
AUTOPSY FINDINGS
Postmortem examination revealed hypertrophic 
cardiomyopathy with heart weight 670 grams 
(RR: 200-430 grams), left ventricular wall thickness 
1.7 cm (RR: 1.0-1.5 cm) and septal thickness 1.1 cm 
(RR: 1.2-1.6 cm). Only part, approximately half, of 
the right ventricle was hypertrophied and the right 
ventricular wall thickness ranged from 0.3 cm to 0.7 cm 
(RR: 0.25-0.50). There was moderate dilatation of the 
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right ventricle and right atrium, reflected in dilatation 
of the tricuspid valve to 13.5 cm in circumference 
(RR: 10.2-10.9 cm). The left ventricle and left atrium 
were not dilated; the mitral valve circumference was 
9 cm (RR: 8.2-9.1 cm). Microscopic examination 
showed extensive myocyte hypertrophy and myocyte 
disarray of anterior and posterior left ventricle and 
right ventricle (Figure 1).
There was interstitial fibrosis with deposition 
of loose connective tissue in most areas of myocyte 
disarray, but some areas had less fibrosis (Figure 2).
The autopsy also showed diffuse severe organizing 
hemorrhagic pericarditis with fibrinous exudate 
covering the surface of the heart. There were extensive 
adhesions, but these were fibrinous adhesions, yielding 
to separation by fingers (Figure 3).
The mitral valve had a 2 cm area of scarring 
and a microscopic vegetation of recent thrombus. 
The tricuspid and pulmonic valves were dilated, but 
otherwise normal. The aortic valve displayed no 
abnormalities.
At autopsy, there was evidence of heart failure: 
pulmonary edema, pleural effusions, passive congestion 
of the liver and ascites. There were 1100 mL of serous 
fluid in the abdominal cavity and 100 ml of fluid in 
each pleural cavity.
The autopsy also showed moderate acute 
pneumonia of the left upper, right upper and right 
middle lobes, and a 2 cm subacute renal cortical infarct.
DISCUSSION
Hypertension cannot explain this patient’s 
myocardial disease. Hypertension would not cause the 
extensive myocyte disarray in anterior and posterior left 
ventricle and right ventricle revealed by microscopic 
examination at autopsy. Furthermore, hypertension 
would not cause the asymmetric hypertrophy of only 
part of the right ventricle.
Neither the clinical history nor the autopsy findings 
provided an etiology for this patient’s organizing 
hemorrhagic pericarditis. Microscopic examination of 
pericardial tissue before and after the patient’s death 
revealed no infecting organisms. Aerobic, anaerobic, 
mycobacterial and fungal cultures of the pericardial 
fluid drained two days antemortem were all negative. 
Although the patient’s INR was slightly elevated, her 
Figure 1. Microscopic examination revealed myocyte 
disarray with branching myocytes maloriented in 
different directions, associated with mild interstitial 
fibrosis (H&E, 40X).
Figure 2. Some areas of myocyte hypertrophy and 
myocyte disarray had less interstitial fibrosis (H&E, 100X).
Figure 3. There was extensive inflammation of 
pericardium with recent hemorrhage, and organizing 
fibrinous exudate (H&E, 40X).
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PTT and platelet count were normal, and autopsy 
revealed no substantial hemorrhage beyond the 
pericardium, so the patient’s pericarditis cannot be 
explained by a bleeding diathesis. Pericardial fluid 
cytology revealed no malignant cells. Autopsy disclosed 
no occult malignancy and microscopic examination of 
pericardium showed no metastasis.
Pericarditis seemed to be the cause of this 
patient’s rapid cardiac decompensation two days 
before she died, when echocardiogram showed a 
large pericardial effusion with evidence of cardiac 
tamponade, but drainage of nearly a liter of pericardial 
fluid provided only transient clinical improvement. 
The patient proceeded to suffer refractory cardiogenic 
shock and arrhythmias culminating in her death. 
Why didn’t therapy for pericarditis save the patient’s 
life? Postmortem examination revealed another 
disease, an underlying myocardial disease, which 
explains why therapy for pericarditis could not save 
her life. This patient’s hypertrophic cardiomyopathy 
explains her heart failure and can be regarded as the 
underlying cause of death. This patient’s hypertrophic 
cardiomyopathy was unsuspected prior to the 
autopsy. So, this case illustrates the value of autopsy 
in revealing the true cause of death. The hypertrophic 
cardiomyopathy was unsuspected because it was 
masked by the pericarditis. So, this case also illustrates 
how comorbidity can mask a crucial diagnosis, in this 
case, the cause of death.
Hypertrophic cardiomyopathy is a heterogeneous 
group of more than 50 genetic diseases caused 
by mutations in genes for the cardiac myocyte 
contractile or sarcomere complex proteins.1 Most 
of these mutations cause asymmetric hypertrophy 
of the interventricular septum and many of them 
cause left ventricular outflow tract obstruction due to 
subaortic stenosis. What they all have in common is 
myocardial hypertrophy as a compensatory response. 
The characteristic microscopic abnormality is myocyte 
disarray, which is well illustrated in this case. Fibrosis and 
small vessel disease are also features of the microscopic 
pathology of hypertrophic cardiomyopathy, but these 
are thought to be secondary and modified by factors 
such as the left ventricular mass, the patient gender 
and maybe local autocrine signaling.2
There are apparent gender and racial differences 
in hypertrophic cardiomyopathy. Women tend to 
be older at diagnosis, with worse symptoms, more 
left ventricular outflow tract obstruction and more 
adverse outcomes.3 Black patients have a hypertrophic 
cardiomyopathy phenotype characterized by lower 
prevalence of the well-recognized echocardiographic 
features, such as left ventricular outflow tract 
obstruction, and have worse exercise capacity and more 
frequent electrocardiographic abnormalities.4,5 The lack 
of asymmetric hypertrophy of the upper septum in 
the black patient of this case report no doubt made it 
difficult to recognize her hypertrophic cardiomyopathy 
on echocardiogram. The apparent gender and racial 
differences in hypertrophic cardiomyopathy might 
be due to factors other than the biology of the 
disease. In particular, the later age at diagnosis, worse 
symptoms and more adverse outcomes in women 
could be due to delay in diagnosis by physicians, 
who think of hypertrophic cardiomyopathy as a male 
disease.
Adverse outcomes of hypertrophic cardiomyopathy 
are increasingly preventable. The worst adverse outcome, 
sudden death due to a ventricular arrhythmia, can be 
prevented with an implantable cardioverter–defibrillator.6 
Heart failure due to left ventricular outflow tract 
obstruction can be treated with pharmacologic therapy 
(beta-blockade and calcium channel blockade), 
transaortic septal myectomy or alcohol septal ablation.6 
Mavacamten is an orally administered allosteric modulator 
of cardiac myosin that inhibits the excessive myosin-actin 
cross-bridge formation underlying excessive contractility 
in hypertrophic cardiomyopathy.1 A recent clinical 
trial has shown that mavacamten can reduce left 
ventricular outflow tract obstruction and improve exercise 
capacity and symptoms in patients with hypertrophic 
cardiomyopathy.7 End-stage disease can be treated 
with heart transplantation. With all of these treatment 
options, mortality from hypertrophic cardiomyopathy can 
be reduced to 0.5% per year, which represents a 90% 
Improvement from 35 years ago.6
Treatability makes the diagnosis of hypertrophic 
cardiomyopathy important. For this purpose, 
cardiac magnetic resonance imaging has joined 
echocardiography as crucial  in the diagnosis 
and management of patients with hypertrophic 
cardiomyopathy.8 Cardiac magnetic resonance imaging 
allows noninvasive assessment of the presence and 
extent of myocardial fibrosis by late gadolinium 
enhancement.8 Late gadolinium enhancement aids 
management because it predicts adverse outcomes. 
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These adverse outcomes can be correlated with 
specific mutations.9 Identifying the specific mutation 
in a patient and the family can greatly facilitate 
determining the prognosis and most appropriate 
management because hypertrophic cardiomyopathy 
is a heterogeneous group of diseases, not a single 
disease. Genetic testing for this purpose is rapidly 
improving with advances in whole genome sequencing, 
proteomics and machine learning.1,10,11 The improving 
diagnostic techniques and treatment modalities have 
implications for screening families.
Hypertrophic cardiomyopathy typically has an 
autosomal dominant pattern of transmission, so the 
children of a patient with hypertrophic cardiomyopathy 
each have a 50% chance of inheriting the condition. 
When an adult patient is found to have hypertrophic 
cardiomyopathy, when should children in the family 
be screened? Guidelines have recommended screening 
children between the ages of 10 and 12 years old 
unless a child meets criteria for early onset of disease, 
but a recent study found that almost 10% of children 
under the age of 10 years old had disease manifest on 
echocardiography and 1% had symptoms of disease.12 
So, screening at a younger age may be appropriate.
Hypertrophic cardiomyopathy is the most common 
inherited cardiomyopathy. With an estimated incidence 
of 1 in 200, there are approximately 750,000 persons 
in the US alone with it and 20 million worldwide.6 
The rapidly evolving diagnostic tests and therapeutic 
strategies for hypertrophic cardiomyopathy make this 
an important diagnosis never to miss.
CONCLUSION
This is the report of a case of hypertrophic 
cardiomyopathy unsuspected clinically because the 
diagnosis was obscured by superimposed pericarditis, 
but revealed by autopsy, demonstrating the value 
of autopsy. Hypertrophic cardiomyopathy is an 
important diagnosis not to miss because it represents 
an autosomal dominant genetic disease and making 
the diagnosis can save the lives of family members.
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